This study compared new-generation drug-eluting stents with bare-metal stents after myocardial infarction, from Taiwan's national health insurance perspective. It used all 10,672 patients stented in 2018, followed to 2023, and matched 3,913 per group by propensity score. Drug-eluting stents were linked to 52%, 48% and 43% lower 1-, 2- and 5-year mortality, and NT$27,839 higher 1-year cost. The incremental cost per death avoided was NT$463,983, NT$241,299 and NT$302,750 at 1, 2 and 5 years. Against the World Health Organization threshold, the authors judged these stents cost-effective. Effectiveness was counted as deaths avoided rather than quality-adjusted life years, and the abstract states no limitations.
Why it is interesting: Drug-eluting stents are the preferred treatment for myocardial infarction, yet some national insurance systems do not reimburse them. This study prices their survival gain over five years in a whole national cohort.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.